Morgan Stanley analyst Tejas Savant maintains $Maravai LifeSciences (MRVI.US)$ with a hold rating, and adjusts the target price from $10 to $7.
According to TipRanks data, the analyst has a success rate of 40.0% and a total average return of -4.0% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Maravai LifeSciences (MRVI.US)$'s main analysts recently are as follows:
Maravai Lifesciences' outlook indicates a lower forecast for Q4 due to delays, general economic weakness in Nucleic Acid Production (NAP) and early-stage exposure in Biologics Safety Testing (BST). The current outlook reveals persistent unclear prospects and margin pressure due to a fixed cost structure, without signs of imminent improvement.
After a sequence of three quarters where Maravai Lifesciences consistently surpassed guidance, the company experienced a setback attributed to the broader weakness in biotech sector spending and the unpredictable nature of customer orders that is typical for their industry.
Maravai Lifesciences reported third-quarter results that did not meet expectations, with performance falling short in both business segments compared to projections. The company observed a decline in research and discovery demand within its NAP segment, an absence of significant one-time orders, and some delays in GMP program timelines extending into 2025.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
摩根士丹利分析師Tejas Savant維持$Maravai LifeSciences (MRVI.US)$持有評級，並將目標價從10美元下調至7美元。
根據TipRanks數據顯示，該分析師近一年總勝率為40.0%，總平均回報率為-4.0%。
此外，綜合報道，$Maravai LifeSciences (MRVI.US)$近期主要分析師觀點如下：
Maravai Lifesciences的展望顯示，由於延遲、核酸生產（NAP）總體經濟疲軟以及生物製劑安全測試（BST）的早期暴露，對第四季度的預測有所降低。當前的前景顯示，由於固定成本結構，前景仍然不明朗，利潤壓力仍然很大，沒有即將改善的跡象。
在連續三個季度中，Maravai Lifesciences持續超過預期，但該公司經歷了挫折，這要歸因於生物技術行業支出普遍疲軟，以及該行業典型的客戶訂單的不可預測性。
Maravai Lifesciences公佈的第三季度業績未達到預期，與預期相比，兩個業務領域的業績均不及預期。該公司觀察到，其NAP領域的研究和發現需求下降，沒有大量的一次性訂單，延遲到2025年的GMP計劃時間表也有所延遲。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
